Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125961001 | 12596100 | 1 | I | 2016 | 20160219 | 20160726 | 20160726 | PER | US-AMGEN-USASL2016021699 | AMGEN | 68.00 | YR | E | M | Y | 0.00000 | 20160726 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125961001 | 12596100 | 1 | PS | KYPROLIS | CARFILZOMIB | 1 | Unknown | 3 WEEKS, THEN OFF 1 WEEK | U | 202714 | INTRAVENOUS INFUSION | ||||||||
| 125961001 | 12596100 | 2 | SS | KYPROLIS | CARFILZOMIB | 1 | Unknown | UNK | U | 202714 | INTRAVENOUS INFUSION | ||||||||
| 125961001 | 12596100 | 3 | SS | KYPROLIS | CARFILZOMIB | 1 | Unknown | 60 | U | 202714 | INTRAVENOUS INFUSION | ||||||||
| 125961001 | 12596100 | 4 | SS | KYPROLIS | CARFILZOMIB | 1 | Unknown | 60 MG, 2 TIMES/WK | U | 202714 | 60 | MG | INTRAVENOUS INFUSION | BIW | |||||
| 125961001 | 12596100 | 5 | SS | NEULASTA | PEGFILGRASTIM | 1 | Unknown | UNK | U | 0 | SOLUTION FOR INJECTION | ||||||||
| 125961001 | 12596100 | 6 | C | COUMADIN | WARFARIN SODIUM | 1 | Oral | 9 MG, QD | 0 | 9 | MG | QD | |||||||
| 125961001 | 12596100 | 7 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | 20 MG, UNK | 0 | 20 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125961001 | 12596100 | 1 | Plasma cell myeloma |
| 125961001 | 12596100 | 5 | Product used for unknown indication |
| 125961001 | 12596100 | 6 | Plasma cell myeloma |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125961001 | 12596100 | Anxiety | |
| 125961001 | 12596100 | Blood potassium decreased | |
| 125961001 | 12596100 | Blood sodium decreased | |
| 125961001 | 12596100 | Chest discomfort | |
| 125961001 | 12596100 | Discomfort | |
| 125961001 | 12596100 | Dyspnoea | |
| 125961001 | 12596100 | Eye pain | |
| 125961001 | 12596100 | Fatigue | |
| 125961001 | 12596100 | Feeling abnormal | |
| 125961001 | 12596100 | Foreign body sensation in eyes | |
| 125961001 | 12596100 | Mobility decreased | |
| 125961001 | 12596100 | Muscle spasms | |
| 125961001 | 12596100 | Pain | |
| 125961001 | 12596100 | Sleep disorder due to a general medical condition | |
| 125961001 | 12596100 | Tremor | |
| 125961001 | 12596100 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125961001 | 12596100 | 1 | 20160111 | 201602 | 0 | |
| 125961001 | 12596100 | 2 | 201603 | 0 | ||
| 125961001 | 12596100 | 3 | 201602 | 0 | ||
| 125961001 | 12596100 | 4 | 201601 | 0 |